Sees Q1 adjusted EBITDA loss $20M with sequential improvements throughout 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Options Volatility and Implied Earnings Moves Today, November 18, 2024
- Absci, Twist Bioscience collaborate to design antibody using generative AI
- Xoma enters $15M royalty monetization arrangement with Twist Bioscience
- Twist Bioscience price target raised to $48 from $45 at Leerink
- Twist Bioscience appoints Mike Fero as chief information officer